Holzer & Holzer, LLC is investigating whether Northwest Biotherapeutics,
Inc. (“Northwest Bio” or the “Company”) (NASDAQ: NWBO) and/or certain of
its officers complied with the federal securities laws in making public
statements regarding its experimental cancer vaccine, DCVax-Direct. On
June 19, 2014, TheStreet.com published a report in which Dr. Aman
Buzdar is quoted as criticizing Northwest Bio for issuing a series of
public statements regarding preliminary results of its ongoing
DCVax-Direct clinical trial. Dr. Buzdar is the vice president of
clinical research at MD Anderson, which is conducting the clinical
trial. The price of Northwest Bio stock has declined significantly on
the report.
If you recently purchased NWBO common stock and have suffered loss on
that investment, you are encouraged to contact Holzer & Holzer, LLC and
its attorney Marshall P. Dees, Esq. via email at mdees@holzerlaw.com,
or via toll-free telephone at (888) 508-6832, to discuss your legal
rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its
practice to vigorous representation of shareholders and investors in
litigation nationwide, including shareholder class action and derivative
litigation. More information about the firm is available through its
website, www.holzerlaw.com
and upon request from the firm. Holzer & Holzer, LLC has paid for the
dissemination of this promotional communication, and Corey D. Holzer is
the attorney responsible for its content.
Copyright Business Wire 2014